Compare Adaptive Biotechnologies Corp (ADPT) vs Devon Energy Corp (DVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Devon Energy Corp — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Devon Energy Corp trades at $43.19 (market cap $48.92B). The key difference: Devon Energy Corp is far larger — about 14.7× Adaptive Biotechnologies Corp's market cap, and Devon Energy Corp pays a 2.45% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DVN | |
|---|---|---|
Market Cap | $3.33B | $48.92B |
Sector | Health | Energy |
52-Week High | $22.37 | $52.07 |
52-Week Low | $10.24 | $31.74 |
Enterprise Value | $3.19B | $55.69B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Devon Energy (DVN) trades at $42.41, up 4.79% on the day, with a bearish technical signal but bullish oscillators. The stock shows strong profitability with a 13.71% net margin and trades at a P/E of 11.24, below sector averages. Recent news highlights activist pressure for asset sales and a pending Q2 2026 earnings report on August 4, 2026.
DVN presents a value opportunity with a consensus price target of $61.60, implying 45% upside, supported by a 71% buy rating from analysts. Risks include oil price volatility, execution of the Coterra merger synergies, and activist investor demands. The company's disciplined capital allocation and strong cash flow generation underpin the bullish outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
